BioCryst Pharma Q4 Adjusted EPS $(0.28) Misses $(0.24) Estimate, Sales $93.40M Beat $90.01M Estimate
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharma (BCRX) reported Q4 adjusted EPS of $(0.28), missing the $(0.24) estimate, but sales of $93.40M exceeded the $90.01M estimate. This represents a 26.32% decrease in losses and a 17.42% increase in sales compared to the same period last year.
February 26, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioCryst Pharma's Q4 earnings showed a miss on EPS but a beat on sales, with significant improvements in both losses and sales compared to last year.
While BCRX missed the EPS estimate, the beat on sales and the year-over-year improvements in both losses and sales suggest a mixed impact on the stock. The EPS miss may concern some investors, but the sales beat and improvements indicate underlying strength, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100